Scar - Pipeline Review, H1 2018
Scar - Pipeline Review, H1 2018
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Scar - Pipeline Review, H1 2018, provides an overview of the Scar (Dermatology) pipeline landscape.
A scar is a permanent patch of skin that grows over a wound. Scars occur at the site of tissue damage and appear as firm red to purple fibrous tissue that over time usually becomes flatter and lighter in color.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Scar - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Scar (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Scar (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Scar and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 5, 2 and 12 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Scar (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Scar - Pipeline Review, H1 2018, provides an overview of the Scar (Dermatology) pipeline landscape.
A scar is a permanent patch of skin that grows over a wound. Scars occur at the site of tissue damage and appear as firm red to purple fibrous tissue that over time usually becomes flatter and lighter in color.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Scar - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Scar (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Scar (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Scar and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 5, 2 and 12 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Scar (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Scar (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Scar (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Scar (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Scar (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Scar (Dermatology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Scar (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Scar (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Scar - Overview
Scar - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Scar - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Scar - Companies Involved in Therapeutics Development
Abzena Plc
Altacor Ltd
BirchBioMed Inc
Clanotech AB
Cotinga Pharmaceuticals Inc
Escape Therapeutics Inc
Kringle Pharma Inc
Pharmaxis Ltd
Promore Pharma
RXi Pharmaceuticals Corp
Synedgen Inc
Vascular BioSciences
Scar - Drug Profiles
albuterol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BTL-slo - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLT-28643 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
decorin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FibroStem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FS-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein for Scar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICX-RHY - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-100IT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
magacizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MG-53 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MMI-0100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Fibrotic Scar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nefopam hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polysaccharide for Wounds and Scars - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PXL-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXI-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Lysyl Oxidase for Scar and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit SOX-9 for Scar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize TGF-Beta Receptor Type 1 and 2 for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tranilast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Scar - Dormant Projects
Scar - Discontinued Products
Scar - Product Development Milestones
Featured News & Press Releases
Feb 16, 2018: BirchBioMed is cleared to begin first-of-its-kind phase II clinical trial for ground-breaking anti-scarring drug
Feb 15, 2018: Promore Pharma Regains Rights for PXL01 Manufacturing
Feb 08, 2018: Bonti Announces Dosing of the First Patient in the SHINE-1 Phase 2 Clinical Study Evaluating EB-001 for Scar Reduction
Feb 01, 2018: Promore Pharma is granted a patent for PXL01 in the US
Jan 02, 2018: Promore Pharma Adjusts Plans for PXL01 in North America
Dec 18, 2017: RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with RXI-109 for Dermal Scarring
Jun 27, 2017: ScarX Achieves Full Enrollment in Human Scar Reduction Trial Safety and Efficacy Results Targeted for Late 2017
May 17, 2017: Promore Pharma files phase III clinical trial application in India
Mar 28, 2017: RXi Pharmaceuticals Granted Patent in Japan for Lead Clinical Candidate RXI-109
Aug 25, 2016: BirchBioMed announces completion of clinical trial for ground-breaking anti-scarring drug
Aug 18, 2016: ScarX announces approval for trial of first clinically-promising scar reduction cream
Apr 28, 2016: RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model
Apr 25, 2016: RXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference
Apr 19, 2016: RXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate RXI-109
Mar 31, 2016: Rxi Pharmaceuticals Strengthens Intellectual Property Portfolio for Dermal Indications
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Scar - Overview
Scar - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Scar - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Scar - Companies Involved in Therapeutics Development
Abzena Plc
Altacor Ltd
BirchBioMed Inc
Clanotech AB
Cotinga Pharmaceuticals Inc
Escape Therapeutics Inc
Kringle Pharma Inc
Pharmaxis Ltd
Promore Pharma
RXi Pharmaceuticals Corp
Synedgen Inc
Vascular BioSciences
Scar - Drug Profiles
albuterol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BTL-slo - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLT-28643 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
decorin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FibroStem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FS-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein for Scar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICX-RHY - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-100IT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
magacizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MG-53 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MMI-0100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Fibrotic Scar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nefopam hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polysaccharide for Wounds and Scars - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PXL-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXI-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Lysyl Oxidase for Scar and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit SOX-9 for Scar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize TGF-Beta Receptor Type 1 and 2 for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tranilast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Scar - Dormant Projects
Scar - Discontinued Products
Scar - Product Development Milestones
Featured News & Press Releases
Feb 16, 2018: BirchBioMed is cleared to begin first-of-its-kind phase II clinical trial for ground-breaking anti-scarring drug
Feb 15, 2018: Promore Pharma Regains Rights for PXL01 Manufacturing
Feb 08, 2018: Bonti Announces Dosing of the First Patient in the SHINE-1 Phase 2 Clinical Study Evaluating EB-001 for Scar Reduction
Feb 01, 2018: Promore Pharma is granted a patent for PXL01 in the US
Jan 02, 2018: Promore Pharma Adjusts Plans for PXL01 in North America
Dec 18, 2017: RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with RXI-109 for Dermal Scarring
Jun 27, 2017: ScarX Achieves Full Enrollment in Human Scar Reduction Trial Safety and Efficacy Results Targeted for Late 2017
May 17, 2017: Promore Pharma files phase III clinical trial application in India
Mar 28, 2017: RXi Pharmaceuticals Granted Patent in Japan for Lead Clinical Candidate RXI-109
Aug 25, 2016: BirchBioMed announces completion of clinical trial for ground-breaking anti-scarring drug
Aug 18, 2016: ScarX announces approval for trial of first clinically-promising scar reduction cream
Apr 28, 2016: RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model
Apr 25, 2016: RXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference
Apr 19, 2016: RXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate RXI-109
Mar 31, 2016: Rxi Pharmaceuticals Strengthens Intellectual Property Portfolio for Dermal Indications
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Scar, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Scar - Pipeline by Abzena Plc, H1 2018
Scar - Pipeline by Altacor Ltd, H1 2018
Scar - Pipeline by BirchBioMed Inc, H1 2018
Scar - Pipeline by Clanotech AB, H1 2018
Scar - Pipeline by Cotinga Pharmaceuticals Inc, H1 2018
Scar - Pipeline by Escape Therapeutics Inc, H1 2018
Scar - Pipeline by Kringle Pharma Inc, H1 2018
Scar - Pipeline by Pharmaxis Ltd, H1 2018
Scar - Pipeline by Promore Pharma, H1 2018
Scar - Pipeline by RXi Pharmaceuticals Corp, H1 2018
Scar - Pipeline by Synedgen Inc, H1 2018
Scar - Pipeline by Vascular BioSciences, H1 2018
Scar - Dormant Projects, H1 2018
Scar - Discontinued Products, H1 2018
Number of Products under Development for Scar, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Scar - Pipeline by Abzena Plc, H1 2018
Scar - Pipeline by Altacor Ltd, H1 2018
Scar - Pipeline by BirchBioMed Inc, H1 2018
Scar - Pipeline by Clanotech AB, H1 2018
Scar - Pipeline by Cotinga Pharmaceuticals Inc, H1 2018
Scar - Pipeline by Escape Therapeutics Inc, H1 2018
Scar - Pipeline by Kringle Pharma Inc, H1 2018
Scar - Pipeline by Pharmaxis Ltd, H1 2018
Scar - Pipeline by Promore Pharma, H1 2018
Scar - Pipeline by RXi Pharmaceuticals Corp, H1 2018
Scar - Pipeline by Synedgen Inc, H1 2018
Scar - Pipeline by Vascular BioSciences, H1 2018
Scar - Dormant Projects, H1 2018
Scar - Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development for Scar, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
COMPANIES MENTIONED
Abzena Plc
Altacor Ltd
BirchBioMed Inc
Clanotech AB
Cotinga Pharmaceuticals Inc
Escape Therapeutics Inc
Kringle Pharma Inc
Pharmaxis Ltd
Promore Pharma
RXi Pharmaceuticals Corp
Synedgen Inc
Vascular BioSciences
Number of Products under Development for Scar, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
COMPANIES MENTIONED
Abzena Plc
Altacor Ltd
BirchBioMed Inc
Clanotech AB
Cotinga Pharmaceuticals Inc
Escape Therapeutics Inc
Kringle Pharma Inc
Pharmaxis Ltd
Promore Pharma
RXi Pharmaceuticals Corp
Synedgen Inc
Vascular BioSciences
